MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab

Study acronym: MAVRiC
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 36 → 47 locations Show 5 more changesShow less
    • Eligibility criteria expanded, about 30 words
    • Secondary endpoints: details revised at 7 of 7 entries
    • Publications: details revised at 1 of 1 entry
    • Study title expanded, about 8 words
    • Study description expanded, about 3 words
  2. Site details revised at 5 of 36 sitesv5
  3. Recruitment opened
    • Start date changed from estimate of Jan 30, 2026 to Jun 4, 2026
    • Trial sites expanded: 29 → 36 locations
    • Study completion pushed from May 15, 2029 to Mar 23, 2033
    v4
  4. Primary completion date: Nov 30, 2032 to May 1, 2029
    • Start date: Sep 30, 2025 to Jan 30, 2026
    • Study sites: 0 to 29
    • Study completion date: Nov 30, 2032 to May 15, 2029
    v3
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate the efficacy and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, who have previously responded to first line (1L) cBTKi + BCL2i therapy (± obinutuzumab) and maintained a response for at least two years post-treatment.
Trial Details
NCT Number NCT07024706
Lead Sponsor AstraZeneca
Collaborators: AbbVie, Genentech, Inc.
Conditions
(from sponsor)		 Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Related terms Leukemia, Lymphocytic, Chronic, B-Cell
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov